Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

@article{Pearson2006SwitchingFI,
  title={Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.},
  author={Ewan Robert Pearson and Isabelle Flechtner and P{\aa}l R. Nj\olstad and Maciej T Malecki and Sarah E Flanagan and Brian Larkin and Frances M. Ashcroft and Iwar Klime{\vs} and Ethel Codner and Violeta M Iotova and Annabelle S. Slingerland and Julian Shield and Jean-Jacques Robert and Jens Juul Holst and Penny M S Clark and Sian Ellard and Oddmund S\ovik and Michel Polak and Andrew T Hattersley},
  journal={The New England journal of medicine},
  year={2006},
  volume={355 5},
  pages={467-77}
}
BACKGROUND Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (K(ATP)) channel, cause 30 to 58 percent of cases of diabetes diagnosed in patients under six months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. Diabetes results from impaired insulin secretion caused by a failure of the beta-cell K(ATP) channel to close in response to increased intracellular ATP. Sulfonylureas close the K(ATP… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS